TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15237766
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg/d)
Study: 10464834
Drug: Inhaled ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled ceftazidime and tobramycin (group A)
Study: 10464834
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (group B)
Study: 2240724
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg/kg IV bolus, followed by 2 mg/min IV drip, with a second bolus of 0.5 mg/kg after 10 minutes)
Study: 2240724
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no lidocaine treatment)
Study: 350499
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin plus 10 mg diazepam
Study: 350499
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sulindac
Study: 350499
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sulindac plus 10 mg diazepam
Study: 12688109
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate nasal spray (400 micrograms daily)
Study: 16504397
Drug: Oral cortisol
Normalized name: Corticool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cortisol (30 mg)
Study: 25265284
Drug: Both intranasal
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intranasal insulin and oral cortisol
Study: 22464310
Drug: Intradetrusor onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intradetrusor onabotulinumtoxinA (doses ≥100 U)
Study: 17647298
Drug: Sertraline (50‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50‐150 mg/day) for 6 weeks
Study: 16291981
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg per day
Study: 16291981
Drug: Sibutramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine plus lifestyle modification counseling (combined therapy)
Study: 8749868
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion (8 mmol over 5 min followed by 65 mmol over 24 h)
Study: 15243278
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RLX) 60 mg daily
Study: 13678475
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 70 mg once weekly
Study: 21254911
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RLX and ALN
Study: 8449578
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg pivampicillin tablet with antacid
Study: 8449578
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg pivampicillin tablet
Study: 3020162
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) at 10 mg/kg body weight at 8 h intervals for 7 days
Study: 31376619
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine in Lantus® and Toujeo®
Study: 27412502
Drug: Short message
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short message service (SMS) intervention for drug consumption motivation
Study: 21534749
Drug: Intravenous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous low-dose magnesium sulphate (0.75 g/h after a loading dose of 4 g)
Study: 21534749
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular regimen (as advocated by Pritchard)
Study: 21534749
Drug: Intravenous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous low-dose magnesium sulphate
Study: 7798851
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular regimen
Study: 16438759
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (2 g in 100 mL of saline solution)
Study: 15372383
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mL of saline)
Study: 12778857
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 5 g/day
Study: 1510454
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of rifampin twice daily on study days 6 and 7 (group A)
Study: 1510454
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of rifampin once daily on days 4, 5, 6, and 7 (group B)
Study: 30554783
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pegbelfermin once a day
Study: 16816757
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous morphine
Study: 11868800
Drug: roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 300 mg daily for 5 days + 80 mg lovastatin
Study: 11868800
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg lovastatin alone
Study: 6093511
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 0.5 g
Study: 31184022
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (Brudi PLUS) 350 mg, 3 times a day for 90 days
Study: 29475928
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Thera tears, Wet therapy, Tears Naturale free)
Study: 1563189
Drug: Antibiotic (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic (14 days, n = 8)
Study: 1563189
Drug: Bronchodilators and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators and physiotherapy
Study: 4082879
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia (low‐dose fentanyl) and systemic morphine for postoperative pain
Study: 25326007
Drug: Listening to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listening to the radio daily
Study: 22496085
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine (DFO) 500 mg intravenous bolus immediately before PPCI followed by a 12-hour infusion (50 mg/kg of body weight)
Study: 12235692
Drug: Investigated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigated group (carbohydrate metabolism disturbances)
Study: 27591241
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IvIg)
Study: 28441896
Drug: Fluoxetine (⩽80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (⩽80 mg/day) for 12 weeks
Study: 12921248
Drug: Cytotoxic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic therapies (chlorambucil, cyclophosphamide)
Study: 8739489
Drug: Continuous SCMC‐Lys
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous SCMC‐Lys 2.7 g once daily
Study: 8739489
Drug: Intermittent SCMC‐Lys
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent SCMC‐Lys 2.7 g
Study: 6797571
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg by mouth twice daily
Study: 25205644
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment
Study: 3625582
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of positive and negative self-verbalizations (PSV + NSV)
Study: 29478012
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (IG): Medication adherence assessment.
Study: 10834422
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline injections)
Study: 24567394
Drug: Repeated intergroup
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated intergroup contact with Spanish-speaking confederates inserted into daily routines for a period of days.
Study: 15025402
Drug: Epinephrine (adrenaline)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine (adrenaline) for out-of-hospital treatment of anaphylaxis; specific dosage not mentioned, but references to EpiPen Jr 0.15 mg and EpiPen 0.3 mg as available auto-injectors.
Study: 15025402
Drug: Epinephrine administration
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine administration methods; subcutaneous injection or inhalation from a pressurized metered-dose inhaler instead of intramuscular injection.
Study: 15025402
Drug: Fixed-dose formulations
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose formulations of epinephrine; specific formulations not mentioned.
Study: 7959501
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg magnesium/day in the form of trimagnesium dieitrate
Study: 3296735
Drug: Methylprednisolone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (both doses)
Study: 3296735
Drug: Methylprednisolone 375
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 375 mg
Study: 24487458
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 200 mcg 10 min prior to tracheal intubation and 6 and 24 h after extubation
Study: 24487458
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 200 mcg 6 and 24 h after extubation
Study: 23457130
Drug: 5 mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/Kg of tranexamic acid (TA)
Study: 23457130
Drug: 15 mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/Kg of tranexamic acid (TA)
Study: 15307697
Drug: Pulmicort inhalation
Normalized name: Pulmicort Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmicort inhalation (WM)
Study: 11606149
Drug: Study medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medications (Enalapril maleate, candesartan cilexetil, metoprolol succinate)
Study: 21107951
Drug: Physiatric and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiatric and kinetic treatment (magnetotherapy)
Study: 18272916
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by goserelin
Study: 18272916
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by tamoxifen
Study: 31157962
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (tamoxifen alone)
Study: 16940192
Drug: 5-methyltetrahydrofolate (5-MTHF)
Normalized name: 5-METHYLTETRAHYDROFOLIC ACID
DrugBank: 5-methyltetrahydrofolic acid (DB04789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-methyltetrahydrofolate (5-MTHF) intravenous infusion
Study: 12657408
Drug: ECT administered
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT administered soon (<210 sec) after anesthetic induction
Study: 12657408
Drug: ECT administered
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT administered later (between 210 sec and 360 sec) after anesthetic induction
Study: 10933121
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (d-amphetamine and Efamol)
Study: 3924814
Drug: Augmentin (amoxycillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentin (amoxycillin 3 g and potassium clavulanate 125 mg)
Study: 3924814
Drug: Amoxycillin 3
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 3 g with probenecid 1 g by mouth
Study: 21135532
Drug: Rowatinex® (special
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rowatinex® (special terpene combination; 3 × 2 capsules/day)
Study: 17229225
Drug: Omeprazole magnesium
Normalized name: Omeprazole Magnesium
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole magnesium 20.6 mg o.m. (Ome-Mg 20)
Study: 17229225
Drug: Famotidine 10
Normalized name: famotidine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 10 mg b.d. (Fam 10)
Study: 11677969
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (control group) before polypectomy
Study: 11677969
Drug: Submucosal epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Submucosal epinephrine injection (1:10,000) before polypectomy
Study: 9476184
Drug: Intravenous L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-arginine
Study: 9476184
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral intake of L-arginine
Study: 2892807
Drug: Ro 16-8714
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 16-8714 (5 mg)
Study: 2892807
Drug: Ro 16-8714
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 16-8714 (10 mg)
Study: 2892807
Drug: Ro 16-8714
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 16-8714 (20 mg)
Study: 23559149
Drug: FOLFOX4 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 plus standard weekly cetuximab (arm 1)
Study: 23559149
Drug: FOLFOX4 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 plus cetuximab (500 mg/m(2)) every second week (arm 2)
Study: 14675411
Drug: Aspirin (75-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75-250 mg/d)
Study: 649865
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug with small monetary incentive
Study: 30958544
Drug: Exenatide 5µg
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide 5µg twice daily for 2 weeks, then 10µg twice daily for 4 weeks
Study: 28603135
Drug: Clopidogrel combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel combined with pantoprazole treatment
Study: 28603135
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment alone (Control)
Study: 23095282
Drug: Anti-tumor necrosis
Normalized name: G 1 (anti-tumor agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tumor necrosis factor-α therapy
Study: 19631849
Drug: Coordinated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coordinated treatment of periodontic and endodontic diseases
Study: 15572280
Drug: Long-acting risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting risperidone (active injections, dummy oral)
Study: 15572280
Drug: Oral risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral risperidone (dummy injections, active oral)
Study: 11988132
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alendronate with 0.625 mg conjugated equine estrogens (CEE)
Study: 11988132
Drug: Cyclic etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclic etidronate with 0.625 mg CEE
Study: 11988132
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alendronate with 2 mg estradiol (E2)
Study: 11988132
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens (nandrolone decanoate plus calcitonin, calcitonin plus growth hormone (GH), pamidronate plus GH)
Study: 20602694
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy adherence
Study: 18436033
Drug: Pentazocine 50
Normalized name: pentazocine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 50 mg/0.5 mg naloxone (females)
Study: 9014625
Drug: Thiopentone 4
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 4 mg kg‐1 followed by a 15‐mg kg‐1 h‐1 continuous infusion
Study: 1515878
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (TBI dose 9 Gy)
Study: 1515878
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (increased TBI dose rate and anthracyclines)
Study: 6381185
Drug: Cimetidine 1.2
Normalized name: cimetidine 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1.2 g/day
Study: 31407775
Drug: Vibration treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration treatment in addition to nasal cast with elastic bandage (group 3)
Study: 23767097
Drug: Reamberin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin (400 ml, two-week infusion)
Study: 20352318
Drug: Diaphragm with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm with lubricant gel
Study: 12514673
Drug: Isosorbide-5-mononitrate (IS-5-MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5-MN) 60 mg daily for 11 months
Study: 2567114
Drug: Atenolol (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50, 100 mg)
Study: 9015908
Drug: Nisoldipine coat-core
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine coat-core (10, 20, 40 mg)
Study: 8673754
Drug: Lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4 mg once daily
Study: 1726000
Drug: Lacidipine 2
Normalized name: lacidipine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 2 mg once daily
Study: 30545532
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) infusion (0.5-1 cc) in addition to HRT
Study: 30545532
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) only
Study: 27481035
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inspiratory muscle training and functional electrical stimulation
Study: 20526194
Drug: Casopitant 150
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant 150 mg + Ondansetron 4 mg
Study: 20526194
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg alone
Study: 19055987
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose (LD) / 75 mg maintenance dose (MD) for 28 days
Study: 19055987
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose (LD) / 10 mg maintenance dose (MD) for 28 days
Study: 15239618
Drug: Celsior (CEL)
Normalized name: Fraxinus excelsior leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celsior (CEL) solution
Study: 3308980
Drug: Amikacin in
Normalized name: amikacin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin in combination with trimethoprim-sulfamethoxazole
Study: 27328486
Drug: Desogestrel (DSG)
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desogestrel (DSG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 21 days followed by seven days of EE 10 mcg (21/7‐active)
Study: 27328486
Drug: Desogestrel (DSG)
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desogestrel (DSG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 21 days followed by no treatment (DSG/EE+no Tx)
Study: 22659624
Drug: bivalirudin 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalirudin 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg intravenous infusion per hour for 4 h
Study: 20924150
Drug: Vinegar drink
Normalized name: Emergen-C Apple Cider Vinegar Drink Mix Powder for Solution (Apple)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinegar drink (100 mL containing 750 mg acetic acid)
Study: 20924150
Drug: Vinegar capsules
Normalized name: Sundance Apple Cider Vinegar Capsules
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinegar capsules (9 capsules containing 750 mg acetic acid in total with 150 mL of water)
Study: 20924150
Drug: Reference (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference (150 mL of water)
Study: 20924150
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of AUC(capsule-ref) and AUC(drink-ref)